摘要
目的 探讨使用低强度Bu/Cy＋ATG预处理方案进行异基因造血干细胞移植治疗恶性血液病的疗效。方法 采用减低剂量的Bu/Cy＋ATG方案,进行异基因造血干细胞移植治疗18例恶性血液病,预处理方案是：马利兰（BU）4 mg/（kg·d）×3,环磷酰胺（CY）60mg/（kg·d）×2,司莫司汀（Me-CCNU）450mg/（m2·d）×1,抗胸腺细胞球蛋白（ATG）3mg/（kg·d）×2。采用环孢素A＋霉酚酸酯（MMF）＋短程MTX预防GVHD。结果 18例患者重建造血,中位随访时间22（3-40）个月,18例中无病存活10例,死亡8例,缓解期移植患者的存活率达66.7%。结论 低强度的Bu/Cy预处理方案,移植相关毒性减小,该方法治疗恶性血液病安全可行。
Objective To study the efficacy of allogeneic hematopoietic stem cell transplantation（Allo-hsct） treating hematopoietic malignant disease patients prepared with dose-reduced Bu/Cy＋ATG conditioning regimen.Methods Eighteen patients who treated with dose-reduced Bu/Cy＋ATG as conditioning regimen（mephalan：4 mg/（kg·d）×3,60 mg/（kg·d）×2,Me-CCNU 450 mg/（m^2·d）×1,ATG 3 mg/（kg·d）×2,and graft-versus-host disease（GVHD） prophylaxis included cyclosporin A,MMF and MTX.Results All patients achieved full donor chimerism without graft failure.After a median follow-up period of 22 months（range,3-40 months）,10 patients survived event-free,in the patients who treated with HSCT,the survival rate was 66.7%.Conclusion The reduced-intensity conditioning regimen using Bu/Cy＋ATG is safe,effective and with less complications in HSCT for patients with hematological malignancies.
出处
《临床医学》
CAS
2008年第7期1-2,共2页
Clinical Medicine
关键词
造血干细胞移植
恶性血液病
预处理
Hematopoietic stem cell transplantation
Hematopoietic malignant disease
Conditioning regimen
